股价表现 - 近期股价表现强劲，过去一个月上涨39.7%，并触及52周新高13.41美元 [1] - 年初至今股价上涨34.3%，表现远超医疗板块4.3%的涨幅和医疗-生物医学与遗传学行业12%的回报率 [1] 业绩表现 - 公司拥有良好的盈利惊喜记录，在过去四个季度均未低于盈利共识预期 [2] - 最近一期财报显示，每股收益为1.06美元，远超共识预期的-0.12美元，营收比共识预期高出20.88% [2] 估值指标 - 公司价值得分为A，增长和动量得分分别为D和C，综合VGM得分为B [5] - 基于当前财年每股收益预期的市盈率为10.8倍，低于同行平均的18.3倍 [6] - 基于追踪现金流的市现率为6.7倍，显著低于同行平均的16.2倍 [6] 投资评级 - 公司目前拥有Zacks排名第一级（强力买入），主要得益于盈利预期的上调 [7] - 公司同时满足Zacks排名为1或2且风格得分为A或B的选股标准 [8] 同业比较 - 同业公司Vericel Corporation（VCEL）拥有Zacks排名第二级（买入），价值得分为D，增长得分为A，动量得分为D [9] - Vericel上一季度盈利超出共识预期75.00，当前财年预期每股收益0.20美元，营收2.7507亿美元 [10] - Vericel过去一个月股价上涨9.6%，远期市盈率为175.58倍，市现率为110.5倍 [10] 行业前景 - 医疗-生物医学与遗传学行业在所有行业中排名前39%，为行业内公司提供了有利的行业环境 [11]

股价表现 - 公司股价在过去一个月内上涨17.3%，并创下52周新高27.08美元 [1] - 公司股价自年初以来累计上涨78.9%，显著跑赢Zacks医疗板块4.3%的涨幅和Zacks医疗-生物医学与遗传学行业12%的回报率 [1] - 同行业公司Exact Sciences Corporation股价在过去一个月上涨12.5% [10] 财务业绩与预期 - 公司在最近四个季度均超出盈利预期，最近一期财报每股收益0.06美元，远超市场预期的-0.1美元，营收超出预期12.32% [2] - 本财年公司预计营收为3.6024亿美元，每股收益为-0.24美元，分别代表83.29%的增长和79.31%的每股收益变化 [3] - 下一财年公司预计营收为4.3941亿美元，每股收益为0.41美元，分别同比增长21.97%和273.61% [3] 投资评级与风格 - 公司获得Zacks Rank 2（买入）评级，得益于稳健的盈利预期修正趋势 [7] - 公司的增长和动量风格得分均为A，价值得分为D，综合VGM得分为B [6] - 同行业公司Exact Sciences Corporation获得Zacks Rank 1（强力买入）评级，增长和动量得分均为A，价值得分为D [9] 行业前景 - Zacks医疗-生物医学与遗传学行业在所有行业中排名前39%，为行业内公司提供了有利的行业环境 [11] - 同行业公司Exact Sciences Corporation本财年预计营收为31.6亿美元，每股收益为0.38美元，其远期市盈率为168.59倍，市现率为11.23倍 [10]

季度业绩表现 - 公司季度每股收益为0.28美元，远超市场预期的每股亏损0.31美元，相比去年同期的每股亏损0.7美元实现扭亏为盈 [1] - 本季度盈利超出预期达190.32%，上一季度实际每股亏损0.14美元亦优于预期的亏损0.28美元，超出预期50% [1] - 在过去四个季度中，公司有三次每股收益超出市场预期，有四次营收超出市场预期 [2] 财务数据 - 截至2025年9月的季度，公司营收达1.6486亿美元，大幅超出市场预期59.45%，去年同期营收为6290万美元 [2] - 对下一季度的市场普遍预期为营收1.1504亿美元，每股亏损0.27美元，对本财年的市场普遍预期为营收4.1387亿美元，每股亏损1.17美元 [7] 市场表现与展望 - 公司股价自年初以来已上涨约72.1%，同期标普500指数涨幅为17.2% [3] - 基于盈利预期修正的积极趋势，公司股票获得Zacks第二级（买入）评级，预计近期表现将优于市场 [6] - 股价的短期走势及未来盈利预期将很大程度上取决于管理层在财报电话会中的评论 [3] 行业比较 - 公司所属的医疗-生物医学与遗传学行业在Zacks行业排名中位列前38%，研究显示排名前50%的行业表现优于后50%的行业，优势超过2比1 [8] - 同业公司PTC Therapeutics预计在即将公布的报告中公布季度每股亏损1.19美元，同比改善14.4%，过去30天内其季度每股收益预期已上调12.4% [9] - PTC Therapeutics预计季度营收为1.756亿美元，较去年同期下降10.8% [10]

Illumina (ILMN) came out with quarterly earnings of $1.34 per share, beating the Zacks Consensus Estimate of $1.16 per share. This compares to earnings of $1.14 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +15.52%. A quarter ago, it was expected that this genetic testing tools company would post earnings of $1.02 per share when it actually produced earnings of $1.19, delivering a surprise of +16.67%.Over the last four quart ...

Gilead Sciences (GILD) came out with quarterly earnings of $2.47 per share, beating the Zacks Consensus Estimate of $2.15 per share. This compares to earnings of $2.02 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +14.88%. A quarter ago, it was expected that this HIV and hepatitis C drugmaker would post earnings of $1.95 per share when it actually produced earnings of $2.01, delivering a surprise of +3.08%.Over the last four ...

Arcellx, Inc. (ACLX) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended September 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the s ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Grifols (GRFS) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Grifols is one of 954 companies in the Medical group. The Medical group currently sits at #5 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the aver ...

季度业绩表现 - 季度每股收益为2.9美元 远超市场预期的1.67美元 相比去年同期的每股亏损0.5美元实现大幅扭亏为盈 [1] - 本季度收益超出预期73.65% 上一季度实际每股收益0.32美元 远超预期的亏损0.03美元 超出幅度达1166.67% [1] - 季度营收达到12.5亿美元 超出市场预期22.25% 相比去年同期的5.0092亿美元实现显著增长 [2] - 公司在过去四个季度中均超出每股收益和营收的市场预期 [2] 股价表现与市场比较 - 公司股价自年初以来已上涨约104.7% 表现远超同期标普500指数17.2%的涨幅 [3] - 股价未来走势将取决于管理层在财报电话会议中的评论以及未来的盈利预期 [3] 未来展望与预期 - 当前市场对下一季度的共识预期为每股收益1.86美元 营收11.8亿美元 对本财年的共识预期为每股收益4.44美元 营收35.6亿美元 [7] - 在本次财报发布前 公司的盈利预期修正趋势好坏参半 这导致其目前获得Zacks第三级（持有）评级 预计近期表现将与市场同步 [6] 行业背景与同业比较 - 公司所属的医疗-生物医学与遗传学行业在Zacks行业排名中位列前38% 研究显示排名前50%的行业表现优于后50%的行业 优势超过2比1 [8] - 同业公司TScan Therapeutics预计在即将发布的报告中公布季度每股亏损0.35美元 同比恶化40% 预期营收为320万美元 同比增长205.1% [9]

Insmed (INSM) came out with a quarterly loss of $1.75 per share versus the Zacks Consensus Estimate of a loss of $1.32. This compares to a loss of $1.27 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -32.58%. A quarter ago, it was expected that this biopharmaceutical developing inhaled treatments for patients battling rare lung diseases would post a loss of $1.3 per share when it actually produced a loss of $1.7, delivering a ...

Apellis Pharmaceuticals, Inc. (APLS) came out with quarterly earnings of $1.67 per share, beating the Zacks Consensus Estimate of $1.03 per share. This compares to a loss of $0.46 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +62.14%. A quarter ago, it was expected that this company would post a loss of $0.44 per share when it actually produced a loss of $0.33, delivering a surprise of +25%.Over the last four quarters, the c ...